For research use only. Not for therapeutic Use.
MM3122 is a selective type II transmembrane serine protease (TMPRSS2) inhibitor with an IC50 value of 0.34 nM. MM3122 effectively blocks TMPRSS2, thereby inhibiting the entry of SARS-CoV-2 and MERS-CoV into human cells[1].
MM3122 (0-1 μM) has inhibitory activity against HGFA, matriptase, hepsin and thrombin with the IC50 values of 32, 0.31, 0.19 and more than 20 nM, respectively[1].
MM3122 (0.1-100 μM) inhibits SARS-CoV-2 calu-3, VSV-SARS CoV-2 chimera calu-3 and MERS VSV pseudotype calu-3 with the EC50 values of 74, 0.43 and 0.87 nM, respectively[1].
MM3122 (i.p., 0-100 mg/kg, daily, 7 days) has no adverse effects, no weight loss or changes in harvested organs (liver, spleen and kidney) compared to controls in NOD-scid IL2Rgnull (NSG) mice[1].
MM3122 (i.p., 16.7 mg/kg, once) has a half-life of 8.6 hours in plasma and 7.5 hours in lung of NSG mice[1].
| Catalog Number | I042897 |
| CAS Number | 2574390-27-3 |
| Synonyms | (2S)-2-[(2-acetamidoacetyl)amino]-N-[(2S)-1-[[(2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pentanediamide |
| Molecular Formula | C31H39N9O6S |
| Purity | ≥95% |
| InChI | InChI=1S/C31H39N9O6S/c1-18(41)36-17-26(43)37-22(13-14-25(32)42)28(45)39-23(16-19-8-3-2-4-9-19)29(46)38-21(11-7-15-35-31(33)34)27(44)30-40-20-10-5-6-12-24(20)47-30/h2-6,8-10,12,21-23H,7,11,13-17H2,1H3,(H2,32,42)(H,36,41)(H,37,43)(H,38,46)(H,39,45)(H4,33,34,35)/t21-,22-,23-/m0/s1 |
| InChIKey | ZEPMYXYJCBQSLH-VABKMULXSA-N |
| SMILES | CC(=O)NCC(=O)NC(CCC(=O)N)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CCCN=C(N)N)C(=O)C2=NC3=CC=CC=C3S2 |
| Reference | [1]. Matthew Mahoney, et al. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Proc Natl Acad Sci U S A. 2021 Oct 26;118(43):e2108728118. |
